

Consolidated Financial Results for Fiscal 2018

(Reference Data of Financial Statements Fiscal 2018 1st Quarter)

August 1, 2018

KAKEN PHARMACEUTICAL CO., LTD.

Corporate Communications

Tel: +81-(0)3-5977-5002

Fax: +81-(0)3-5977-5131

Email: koho@kaken.co.jp

1. Summary of Consolidated Financial Statements for Fiscal 2018 1st Quarter

(Figures less than one million yen have been omitted)

	FY2017 1st Q	FY2017	FY2018 1st Q	Y o Y increase (decrease)		Plan FY2018	Y o Y increase (decrease)	
				Yen	%		Yen	%
Net sales	24,967	98,430	24,135	(832)	96.7%	94,800	(3,630)	96.3%
Operating income	7,649	27,496	5,647	(2,001)	73.8%	22,500	(4,996)	81.8%
Ratio of net sales	30.6%	27.9%	23.4%			23.7%		
Ordinary income	7,813	27,854	5,817	(1,996)	74.4%	22,800	(5,054)	81.9%
Ratio of net sales	31.3%	28.3%	24.1%			24.1%		
Net income	5,463	19,043	4,035	(1,428)	73.9%	16,400	(2,643)	86.1%
Ratio of net sales	21.9%	19.3%	16.7%			17.3%		
Comprehensive income	6,300	20,753	4,232	(2,067)	67.2%			
R&D expenses	1,836	8,152	3,579	1,743	194.9%	11,700	3,548	143.5%

2. Breakdown of Sales by Main Pharmaceuticals and Medical Devices

(Figures less than one million yen have been omitted)

	FY2017 1st Q	FY2017	FY2018 1st Q	%	Plan FY2018	%
Anti-osteoarthritis Artz	7,669	28,351	6,419	83.7%	24,800	87.5%
Anti-nail fungus Clenafin	5,741	22,185	6,015	104.8%	22,900	103.2%
Post-operative anti-adhesive Seprafilm	2,639	10,162	2,480	94.0%	10,200	100.4%
Wound healing agent Fiblast Spray	932	3,616	799	85.7%	3,100	85.7%
Anti-hyperlipidemia Lipidil	1,123	4,208	785	69.9%	2,900	68.9%
Generic products	3,011	11,793	2,696	89.5%	11,200	95.0%